Benedicte Caron
Overview
Explore the profile of Benedicte Caron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Honap S, Caron B, Ollech J, Fischman M, Papamichael K, de Jong D, et al.
Dig Dis Sci
. 2025 Jan;
PMID: 39869163
Background: Therapeutic drug monitoring is important for optimizing anti-tumor necrosis factor-α (TNF-α) therapy in inflammatory bowel disease. However, the exposure-response relationship has never been assessed in pouchitis. Aims: To explore...
2.
Quilliot D, Bonsack O, Mahmutovic M, Peyrin-Biroulet L, Caron B
Clin Nutr ESPEN
. 2024 Dec;
65():375-381.
PMID: 39662590
Background: Undernutrition is purportedly highly prevalent in inflammatory bowel diseases (IBD). While several risk factors have been identified, the impact of widespread eating behaviors such as food exclusions and therapeutic...
3.
Mancheron A, Dumas A, Nion Larmurier I, Landman C, Peyrin Biroulet L, Caron B, et al.
J Crohns Colitis
. 2024 Nov;
PMID: 39575831
Background And Aims: Inflammatory Bowel Disease (IBD) are known to impact patients 'sexual lives. The aim of this study is to create and validate a sexual QoL designed for youth...
4.
Le Cosquer G, Kirchgesner J, Gilletta De Saint Joseph C, Seksik P, Amiot A, Laharie D, et al.
Clin Gastroenterol Hepatol
. 2024 Nov;
PMID: 39505240
Background & Aims: Breast cancer is the most common malignancy observed in patients with inflammatory bowel diseases (IBD). The aim of our study was to evaluate incident cancer rate (recurrence...
5.
Caron B, Honap S, Peyrin-Biroulet L
J Crohns Colitis
. 2024 Oct;
18(Supplement_2):ii3-ii15.
PMID: 39475082
Background And Aims: The incidence of inflammatory bowel diseases [IBD] has risen over the past decade to become a global issue. The objectives of this review were to describe the...
6.
Sequier L, Caron B, Danese S, Peyrin-Biroulet L
Expert Opin Biol Ther
. 2024 Sep;
24(10):1145-1169.
PMID: 39269146
Introduction: The approval of biosimilars in the management of inflammatory bowel diseases (IBDs) has offered an answer to a growing concern about healthcare costs, and availability of treatments. Several studies...
7.
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID
Caron B, Seksik P, Buisson A, Wils P, Savoye G, Stefanescu C, et al.
Therap Adv Gastroenterol
. 2024 Aug;
17:17562848241265776.
PMID: 39119370
Background: Several adalimumab preparations are now available for patients with inflammatory bowel disease (IBD). Comparative satisfaction and tolerability are unknown. Objectives: This study investigated IBD patient satisfaction with approved adalimumab...
8.
Sequier L, Caron B, Loeuille D, Honap S, Jairath V, Netter P, et al.
Aliment Pharmacol Ther
. 2024 Jul;
60(6):686-700.
PMID: 39076140
Background: Methotrexate, an immunosuppressant used for the treatment of inflammatory bowel disease (IBD) for over 30 years, remains underused compared to thiopurines. Aims: To review the efficacy, safety, optimal dosing...
9.
DAmico F, Massimino L, Palmieri G, Dal Buono A, Gabbiadini R, Caron B, et al.
Eur J Clin Invest
. 2024 Jul;
54(11):e14283.
PMID: 38979834
Background And Aims: Subcutaneous (SC) formulations of infliximab (IFX) and vedolizumab (VDZ) are approved for the treatment of inflammatory bowel diseases (IBDs). Our aim was to evaluate the effectiveness of...
10.
Fumery M, Caron B, Hebuterne X, Altwegg R, Roblin X, Stefanescu C, et al.
Clin Gastroenterol Hepatol
. 2024 May;
22(12):2451-2458.e1.
PMID: 38729389
Background & Aims: The aim of this study was to assess the long-term effectiveness and safety of risankizumab maintenance treatment in a large real-world cohort of patients with Crohn's Disease...